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SUMMARY
Setting—Even in persons with complete treatment of their first tuberculosis (TB) episode, 
patients with a TB history are at higher risk for having TB.
Objective—Describe factors from the initial TB episode associated with recurrent TB among 
patients who completed treatment and remained free of TB for at least 12 months.
Design—US TB cases, stratified by birth origin, during 1993–2006 were examined. Cox 
proportional hazards regression was employed to assess the association of factors during the initial 
episode with recurrence at least 12 months after treatment completion.
Results—Among 632 US-born patients, TB recurrence was associated with age 25–44 (adjusted 
hazard ratio [aHR] 1.77, 99% confidence interval [CI] 1.02–3.09, attributable fraction [AF] 1%–
34%), substance use (aHR 1.57, 99%CI 1.23–2.02, AF 8%–22%), and treatment supervised by 
health departments (aHR 1.42, 99%CI 1.03–1.97, AF 2%–28%). Among 211 foreign-born 
patients, recurrence was associated with HIV infection (aHR 2.24, 99%CI 1.27–3.98, AF 2%–9%) 
and smear-positive TB (aHR 1.56, 99%CI 1.06–2.30, AF 3%–33%).
Conclusion—Factors associated with recurrence differed by birth origin and might be useful for 
anticipating greater risk for recurrent TB among certain patients with a TB history.
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Compared to patients with no previous history of tuberculosis (TB), patients with a history 
of TB are at higher risk for having TB1-3; additionally, patients with recurrent TB have 
poorer outcomes, including lower treatment completion and higher mortality.4,5 In addition 
to incomplete treatment of the first TB episode, factors associated with recurrence have 
included substance use, sputum smear-positive disease, cavitary pulmonary disease, and 
HIV infection.6-10
Elucidating factors associated with recurrence might help TB control programs and clinical 
providers recognize those patients with a history of TB who have a greater risk for recurrent 
TB so that they can explore ways of minimizing that risk. In a low-incidence setting like the 
United States, most recurrence has been attributed to reactivation, or incomplete cure of the 
first TB episode, rather than a new TB exposure resulting in reinfection.10-11
Internationally, patients who complete treatment for TB are classified as “cured” if their 
bacteriologically confirmed TB converts to being smear- or culture-negative; otherwise, they 
are classified as having “treatment completed”.12 When these two groups of patients are 
diagnosed with TB again later, they are considered to have “TB relapse,” regardless of how 
much time has elapsed.12 In contrast, the US National TB Surveillance System, which does 
not distinguish between “cure” and “treatment completion”, defines “recurrence” as verified 
TB disease in patients with a previous diagnosis who were discharged or lost to supervision 
for at least 12 months since the last clinical encounter for TB treatment; any TB diagnosis 
that occurs sooner is considered a continuation of the same TB case for national surveillance 
purposes (i.e., not counted as incident TB).13 Others have termed this US definition “late 
recurrence”8, because it explicitly excludes the majority of TB relapses which occur during 
and immediately following treatment.9 Applying this definition, the annual proportion of TB 
cases that are recurrences has persisted at a stable 4.2%–5.7% since the 1980s, despite the 
decline in annual TB incidence from 11 cases to 3 per 100,000 in the United States.4,13-14
Because we were interested in the group of former TB patients least expected to experience 
recurrence, we focused our analysis on those US patients who had uncomplicated TB that 
was eligible for treatment completion within 12 months, who completed treatment of the 
initial TB episode, and whose TB did not relapse within a year of treatment completion. We 
used national TB surveillance data to match individuals’ initial and recurrent TB episodes 
and then determine factors associated with later recurrence.
STUDY POPULATION AND METHODS
Source population and inclusion criteria
We retrospectively examined a 13-year cohort in the National TB Surveillance System of the 
US Centers for Disease Control and Prevention.14 The source population for this analysis 
included all verified incident TB cases14 reported by health departments in the 50 states and 
the District of Columbia as being diagnosed and starting treatment for TB during 1993–2005 
and then having uncomplicated TB that was eligible for treatment completion within 12 
months13 and did, in fact, complete treatment both within 12 months and by the end of 2005.
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Recurrent case ascertainment and validation process
The US National Tuberculosis Surveillance System does not include patient names, so we 
were unable to replicate the methodology for a similar but smaller California cohort of 148 
recurrences.8 Instead, multiple TB episodes in the same patient were detected by a novel 
algorithm: multiple case reports from the same state with the same sex, birthdate, race, 
ethnicity, birth origin (US-born or foreign-born), and country of birth; further, the first TB 
episode year (1993–2005) had to match the previous TB episode year as reported during the 
recurrent TB episode (1994–2006). Confidentially, public health officials in the jurisdictions 
then confirmed which pairs of records represented two episodes of TB in the same patient.
Presumed single-episode comparison group
All remaining reported cases during 1993–2005 with no history of TB, a known birth origin, 
and that otherwise met the same inclusion criteria, were classified as the presumed single-
episode comparison group, in that they were presumed not to have TB again during 1994–
2006 and were assigned a censoring date for the survival analysis of December 31, 2006.
Analysis
The outcome of interest was having recurrent TB, and 27 reported demographic, clinical, 
and treatment-related factors at the time of the initial TB episode were considered as 
potential risk factors. Because birth origin strongly influences the epidemiology of TB in the 
United States,13 we stratified our analysis by US and foreign birth. Missing data in each 
category were included in the denominator for calculating percentages but not shown in the 
descriptive data results unless the proportion in any one stratum was >2%.
Owing to the large dataset size and large number of variables considered, we chose a 
statistical significance cutoff level of P < 0.01. Differences in initial TB episode 
characteristics were contrasted using Pearson’s chi-square tests. Cox proportional hazards 
regression with the outcome of recurrent TB was used to simultaneously consider multiple 
characteristics of the initial TB episode and determine the adjusted hazard ratio (aHR) and 
corresponding 99% confidence interval (CI) for each risk factor. The fraction of TB 
recurrence attributable to each risk factor, as measured at the time of the initial TB episode, 
was estimated by multiplying ([aHR − 1]/aHR) by the prevalence of that risk factor among 
persons who later experienced recurrence. Statistical data analysis was conducted with SAS 
version 9.3 (Statistical Analysis Software Institute, Cary, NC, USA).
Data were collected as part of routine TB surveillance; therefore, this retrospective analysis 
using existing data was not considered research and did not require approval by an 
institutional review board. The identities of persons were held confidential in accordance 
with Section 308(d) of the US Public Health Service Act.
RESULTS
Across the United States, 2702 persons who experienced recurrent TB during 1994–2006 
had a previous TB diagnosis in 1993 or later, and appeared to reside in the United States for 
both episodes. Of these, 1714 appeared to reside in the same US state for both episodes; 
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states confirmed 1533 of those. These 1533 patients were further refined to the subset of 843 
whose first TB episode was uncomplicated and eligible for treatment completion within 12 
months, who completed treatment, and whose TB did not relapse within a year (Figure 1); 
their median follow-up time was 4 years (i.e., 50% of recurrent cases had occurred between 
1 and 4 years later). The remaining 223 522 cases were examined for eligibility as the 
presumed single-episode comparison group, yielding 142 221 persons for this analysis 
(Figure 2); their median follow-up time was 8 years.
Among the 843 persons with recurrent TB, the median time between TB episodes was 3.3 
and 2.7 years for US-born and foreign-born persons, respectively. For foreign-born persons, 
mean duration of stay in the US was 9 years (interquartile range [IQR] 1–13 years) for those 
with a single TB episode and 11 years (IQR 2–16 years) before the initial TB episode for 
those with recurrent TB later.
At initial TB episode, US-born patients with recurrent TB were more frequently aged 25–64 
years, male, or non-Hispanic black, to have used substances (i.e., excess alcohol or non-
injection or injection drugs) or experienced homelessness during the previous 12 months, to 
be HIV-infected, or to have pulmonary, smear- and culture-positive, cavitary disease (P < 
0.001) (Table 1). Foreign-born patients later diagnosed with recurrent TB were more likely 
to be aged 25–64 and to have HIV or sputum smear-positive TB than were foreign-born 
patients in the single-episode comparison group (P < 0.001) (Table 1).
Table 2 shows the results of the Cox proportional hazards model for factors associated with 
recurrent TB disease, stratified by birth origin. Having the initial TB episode occur after 
2002 appeared protective against recurrence for both US-born and foreign-born persons. 
Among the US-born, factors during the initial episode independently associated with 
recurrence included age 25–44 years (aHR 1.77, 99%CI 1.02–3.09), substance use (aHR 
1.57, 99%CI 1.23–2.02), and treatment supervised by health departments (aHR 1.42, 99%CI 
1.03–1.97). Foreign-born patients later diagnosed with recurrent TB were more likely HIV-
infected (aHR 2.24, 99%CI 1.27–3.98) or to have smear-positive TB (aHR 1.56, 99%CI 
1.06–2.30) during the initial episode. Corresponding attributable fractions among the US-
born were 22% (1%–34%) for age 25 44 years, 16% (8%–22%) for substance use, and 17% 
(2%–28%) for health department treatment; and among the foreign-born were 6% (2%–9%) 
for HIV infection and 21% (3%–33%) for smear-positive TB at the time of the initial TB 
episode.
DISCUSSION
This analysis of US national surveillance data found that persons with uncomplicated TB 
who completed treatment within 12 months, and whose TB did not relapse within a year, 
had certain identifiable risk factors at the time of their initial TB episode associated with a 
higher risk of TB recurrence later, and these factors differed on the basis of birth origin. In 
general, social risk factors were associated with recurrent TB among US-born patients, 
whereas clinical characteristics appeared to play a greater role among foreign-born patients. 
Among US-born patients, recurrence was associated with ages 25–44 years, substance use, 
and treatment managed by a health department during the initial TB episode. Among 
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foreign-born patients, initial episode factors associated with recurrence were ages 45–64 
years, HIV infection, and smear-positive disease.
Although US public health departments continue to play an integral role in TB treatment and 
adherence, including provision of directly observed therapy, our study found that recurrent 
TB among US-born was associated with treatment by health departments. This unexpected 
association might be explained by confounding by indication (i.e., some unmeasured social 
risk factor that led to both initial treatment in the public sector as well as later recurrence). 
For example, the finding of substance use as a risk factor for recurrent TB underscores the 
importance in countries with low TB incidence of engaging with society’s most socially 
marginalized and vulnerable populations to address broader determinants of health.15-18
In 2003, American guidelines were revised to more forcefully advocate for the standard 4-
drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol.9,19 Even after 
adjustment for secular trend, being treated with only isoniazid and rifampin had a borderline 
association (99%CI 0.92–2.64) with TB recurrence among the US-born. Although this 
suboptimal regimen was rarely used (<5% of the study population), this finding further 
validates the importance of current treatment recommendations.9
Interestingly, we found HIV infection to be independently associated with TB recurrence 
among foreign-born but not among US-born patients. This finding might be due to US-born 
patients’ increased access to healthcare, including better linkages to HIV treatment and care, 
compared to foreign-born patients. Additionally, if a substantial proportion of US-born, 
single-episode patients had HIV prior to antiretroviral therapy introduction, then other 
opportunistic infections may have caused death before TB could recur, blunting the 
contribution of HIV to the risk of TB recurrence among US-born patients in this analysis. 
Likewise, our survival analysis assigned everyone in the comparison group the same 
censoring date as their end point, but persons with other immunocompromising conditions 
or advanced age were more likely to have an earlier, but unknown, censoring date.
Several other limitations also deserve mention. We were limited to the information routinely 
collected in the US National Tuberculosis Surveillance System, which at the time did not 
include potentially important variables such as diabetes, tobacco use, and nutrition status. 
Our study population represents longtime US residents well, but our findings might be less 
generalizable to more recent immigrants or geographically mobile individuals. Patients in 
the single-episode comparison group who experienced TB recurrence in another state/
country or after 2006 were misclassified. Nevertheless, of the 2702 total persons who 
appeared to be living in the United States for both of their TB episodes during 1993–2006, 
over half (1533) were confirmed by states as having been accurately identified by our 
algorithm. In addition, our internal analysis did not reveal any geographic trends or 
differences (data not shown). Finally, because our study period occurred before widespread 
use of TB genotyping, only 24 patients, or 2.8% of our study population, had TB genotyping 
results available for both TB episodes, precluding us from being able to examine our 
assumption that the majority of these recurrences had the etiology of reactivation (i.e., 
incomplete cure of the first TB episode). As genotyping surveillance coverage subsequently 
increased to 88.2%,20 future analyses will be able to discriminate between the proportions of 
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recurrent TB attributable to endogenous reactivation and exogenous reinfection in the United 
States.
CONCLUSIONS
This is the largest and first nationally representative study in the United States to examine 
previous TB episodes in persons who later experienced TB recurrence. Clinicians are 
already aware that a history of TB, even among those considered to have completed 
adequate treatment, is an independent risk factor for TB. This analysis suggests particular 
factors, which might differ by birth origin, are identifiable during the initial episode. While 
rapid diagnosis and treatment remain the mainstays of TB control, being able to recognize 
those patients at highest risk of recurrence might lead to better integration with substance 
abuse programs and optimal management of HIV infection at the time of and following the 
initial TB episode.
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Flow diagram showing inclusion criteria for persons with recurrent tuberculosis at least 12 
months after treatment completion of previous tuberculosis episode, United States, 1993–
2006
* Eligibility for completion of tuberculosis treatment within 12 months is defined as follows: 
patients have to be alive at diagnosis; initiate treatment; not die during treatment; and not 
have an initial isolate that is rifampin-resistant, have meningeal disease, or be a pediatric 
patient (aged <15) with miliary disease or positive M. tuberculosis blood culture.
† The US surveillance definition of tuberculosis recurrence is verified disease in a person 
with a previous diagnosis of tuberculosis who was discharged or lost to supervision for at 
least 12 months since the last clinical encounter for tuberculosis treatment.
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Flow diagram showing inclusion criteria for comparison group presumed to have single 
tuberculosis episode only, United States, 1993–2006
* Eligibility for completion of tuberculosis treatment within 12 months is defined as follows: 
patients have to be alive at diagnosis; initiate treatment; not die during treatment; and not 
have an initial isolate that is rifampin-resistant, have meningeal disease, or be a pediatric 
patient (aged <15) with miliary disease or positive M. tuberculosis blood culture.
† The US surveillance definition of tuberculosis recurrence is verified disease in a person 
with a previous diagnosis of tuberculosis who was discharged or lost to supervision for at 
least 12 months since the last clinical encounter for tuberculosis treatment.
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